leisure time -WSS

leisure time

author：explore 2025-10-01 12:11:54 - browse：51824

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

WSS

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

An inside look at PIPEs, biotech's buzzy new financing tool

Crowdfunding for unproven stem cell procedures spreads misinformation

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

entertainment

leisure time

leisure time

Novavax promises a turnaround & Lilly roils the obesity market

An inside look at PIPEs, biotech's buzzy new financing tool

As demand for Covid shots wanes, Moderna seeks its next success

AstraZeneca loses challenge to Medicare drug price negotiation

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

State Dept. review finds Biden bears some blame for Afghanistan failures

How Robert F. Kennedy Jr. distorted vaccine science

State Dept. review finds Biden bears some blame for Afghanistan failures

In search for therapies for solid tumors, companies turn to claudin

knowledge

AstraZeneca loses challenge to Medicare drug price negotiation

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Prescription digital therapeutics are key to pharma’s future

Clinical trials giant ICON acquires HumanFirst

Congress gives doctors Medicare pay bump

RaDonda Vaught to speak at CommonSpirit event on patient safety

hotspot

entertainment

Wikipedia

knowledge